

2. The authors implied isolation of *Rhodococcus* from culture media, but they initiated empirical therapy without performing antimicrobial drug susceptibility test. The antibiogram test is necessary for appropriate treatment of *Rhodococcus* infection and decreasing antibiotic resistance burden.

Kiarash Ghazvini^{a,b}

Masoud Keikha^{a,b}

^a*Antimicrobial Resistance Research Center
Mashhad University of Medical Sciences
Mashhad, Iran*

^b*Department of Microbiology and Virology
Faculty of Medicine
Mashhad University of Medical Sciences
Mashhad, Iran*

E-mail: masoud.keykha90@gmail.com

<https://doi.org/10.1016/j.transproceed.2019.10.005>

[1] Alfano G, Ventura P, Fontana F, Marcacci M, Ligabue G, Scarlini S, et al. *Rhodococcus equi* pneumonia in kidney transplant recipient affected by acute intermittent porphyria: a case report. *Transplant Proc* 2019;51:229–34.

[2] Goodfellow M, Alderson G, Chun J. *Rhodococcal* systematics: problems and developments. *Antonie van Leeuwenhoek* 1998;74:3–20.

[3] Majidzadeh M, Fatahi-Bafghi M. Current taxonomy of *Rhodococcus* species and their role in infections. *Eur J Clin Microbiol Infect Dis* 2018;37:2045–62.

[4] Golub B, Falk G, Spink WW. Lung abscess due to *Corynebacterium equi* report of first human infection. *Ann Intern Med* 1967;66:1174–7.

[5] Bell KS, Philp JC, Aw DW, Christofi N. The genus *Rhodococcus*. *J Appl Microbiol* 1998;85:195–210.

[6] Prescott JF. *Rhodococcus equi*: an animal and human pathogen. *Clin Microbiol Rev* 1991;4:20–34.

[7] Lin WV, Kruse RL, Yang K, Musher DM. Diagnosis and management of pulmonary infection due to *Rhodococcus equi*. *Clin Microbiol Infect* 2019;25:310–5.

[8] Woods GL, Brown-Elliott BA, Conville PS, Desmond EP, Lin G, Pfyffer GE, et al. Susceptibility testing of mycobacteria, *Nocardia* and other aerobic actinomycetes. Approved standard. 2nd edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI report #M24-A2.

[9] Yamshchikov AV, Schuetz A, Lyon GM. *Rhodococcus equi* infection. *Lancet Infect Dis* 2010;10:350–9.

[10] Giguère S, Lee E, Williams E, Cohen ND, Chaffin MK, Halbert N, et al. Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in *Rhodococcus equi* isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of *R. equi*. *J Am Vet Med Assoc* 2010;237:74–81.

Author's Response



We thank Ghazvini et al for their comment to the case report “*Rhodococcus equi* Pneumonia in a Kidney Transplant Recipient Affected by Acute Intermittent Porphyria” [1].

As precisely reported by the authors, *Rhodococcus equi* is Gram-positive, occasionally acid-fast, bacterium living in soil water, decaying plant and stool of herbivores [2]. In humans, *Rhodococcus equi* causes opportunistic infections occurring principally in immunosuppressed patients, including solid organ and hematopoietic stem cell recipients and people living with human immunodeficiency virus. Given that *Rhodococcus equi* is widely present in the environment, impairment of the immune response rather than exposure to the pathogen has been considered the main predisposing factor for the development of this infection.

Rhodococcus equi infection frequently involves lung parenchyma and manifests with pneumonia, high fever, fatigue and chest pain. Extrapulmonary organ involvement occurs only in 25% of cases [3].

In the last decades, ameliorations of the laboratory techniques for the identification of *Rhodococcus species* has increased the rate of recognition of this bacterium. The pathogen is commonly detected from biological specimens such as sputum, bronchoalveolar lavage fluid, pleural fluid, abscess aspirate, peritoneal fluid, cerebrospinal fluid, lymph nodes, and tissue culture from any suspected affected organ. Positive blood culture is seen only in patients with hematogenous spread of lung infection [2].

Rhodococcus equi regularly grows on enriched media including blood and chocolate agar. On Sabouraud agar and purple lactose agar, the colonies turn salmon-pink due to the production of a characteristic substance. *Rhodococcus equi* is a facultative intracellular pathogen that resides in macrophages and causes granulomatous inflammation. It is a slow-growing bacterium without hemolytic activity when cultured in blood agar. Its shape changes from coccoid form in solid media to long curved clubbed form in liquid media.

In our laboratory, *Rhodococcus equi* grew on sheep blood and chocolate agar after 7 days of incubation. Identification of the *Rhodococcus* species occurred by the structural characterization of mycolic acids through mass spectrometry [4]. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [5], the pathogen was susceptible to levofloxacin (minimal inhibitory concentration [MIC] of 1 MIC mg/L). MIC testing was also performed for erythromycin, vancomycin, and teicoplanin (MIC of 12, 0.38, and 0.50, respectively), but antimicrobial sensitivity was not furnished because EUCAST did not recommend any interpretive breakpoints. Our choice to treat *Rhodococcus equi* infection with azithromycin and meropenem was based both on the ability of azithromycin to have intracellular penetration and the documented in-vitro activity of meropenem against *Rhodococcus equi* [6]. Although we are aware that antimicrobial susceptibility testing is necessary for appropriate treatment of infections, in vitro antimicrobial susceptibilities of *Rhodococcus equi* are not standardized; therefore, antibiotic choice is still essentially based on single-center experience.

Gaetano Alfano, MD*

*Surgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy;
Nephrology, Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy*

Francesco Fontana, MD, PhD

Nephrology, Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy

Giovanni Guaraldi, Professor

Clinic of Infectious Diseases, University Hospital of Modena, Modena, Italy

Gianni Cappelli, Professor

*Surgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy;
Nephrology, Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy*

*Address correspondence to Gaetano Alfano,
E-mail: gaetano.alfano@unimore.it*

<https://doi.org/10.1016/j.transproceed.2019.11.030>

[1] Alfano G, Ventura P, Fontana F, Marcacci M, Ligabue G, Scarlini S, et al. *Rhodococcus equi* pneumonia in kidney transplant recipient affected by acute intermittent porphyria: a case report. *Transplant Proc* 2019;51:229–34.

[2] Yamshchikov AV, Schuetz A, Lyon GM. *Rhodococcus equi* infection. *Lancet Infect Dis* 2010;10:350–9.

[3] Stewart A, Sowden D, Caffery M, Bint M, Broom J. *Rhodococcus equi* infection: a diverse spectrum of disease. *IDCases* 2019;15:e00487.

[4] Hsu F-F, Soehl K, Turk J, Haas A. characterization of mycolic acids from the pathogen *Rhodococcus equi* by tandem mass spectrometry with electrospray ionization. *Anal Biochem* 2011;409:112–22.

[5] EUCAST. Clinical breakpoints and dosing of antibiotics. http://www.eucast.org/clinical_breakpoints/. [Accessed 01.10.19].

[6] Nordmann P, Ronco E. In-vitro antimicrobial susceptibility of *Rhodococcus equi*. *J Antimicrob Chemother* 1992;29:383–93.